Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 72, Issue 1, Pages 3-6Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2012-202361
Keywords
-
Categories
Funding
- Abbott
- Astra-Zeneca
- BMS
- Celgene
- Glaxo
- Janssen
- Lilly
- Medimmune
- MSD
- Novartis-Sandoz
- Novo-Nordisk
- Pfizer
- Roche
- Teva
- UCB
Ask authors/readers for more resources
In this viewpoint, we summarise three different lines of evidence suggesting that current biological therapies directed at different molecules or cells have similar efficacy in rheumatoid arthritis and target similar populations of patients; therefore, distinct biological effects of targeted therapies may not account for differences in response. Moreover, currently available individual biomarkers or multiple biomarker sets do not provide information beyond that conveyed by clinical disease activity. Smart and novel research designs will have to be developed to find pertinent biomarkers. Until then, the focus of clinicians may have to solely rest on clinical disease activity assessment and targeting remission or low disease activity rapidly.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available